Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 28, 2022 18:17 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2022...
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022
February 22, 2022 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year...
Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
February 01, 2022 08:00 ET
|
Sarepta Therapeutics, Inc.
Collaboration combines Sarepta’s proprietary gene editing technologies and GenEdit’s non-viral delivery platform to create new genetic medicines for patients with neuromuscular diseasesInitial results...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2022 18:15 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2022...
Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy
January 10, 2022 10:50 ET
|
Sarepta Therapeutics, Inc.
Participants from the placebo crossover group in Part 2 of Study SRP-9001-102 , scored 2.0 points higher on the mean North Star Ambulatory Assessment (NSAA) 48 weeks after treatment with SRP-9001...
Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022 08:32 ET
|
Sarepta Therapeutics, Inc.
Presentation on Monday, Jan. 10, 2022, to include topline results from Part 2 of Study SRP-9001-102 CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc....
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2021 20:45 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2021...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2021 18:17 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2021...
Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
November 17, 2021 08:31 ET
|
Sarepta Therapeutics, Inc.
Gilmore O’Neill, M.B., M.M.Sc., will depart the Company and serve in a consulting capacity through March 31, 2022 CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc....
Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
November 17, 2021 08:30 ET
|
Sarepta Therapeutics, Inc.
A renowned expert in protein engineering, Dr. Mayo brings extensive scientific expertise and strong business acumen to the Company’s board CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) --...